1
|
Alexander EC, Wadia TH, Ramnarayan P. Effectiveness of high flow nasal Cannula (HFNC) therapy compared to standard oxygen therapy (SOT) and continuous positive airway pressure (CPAP) in bronchiolitis. Paediatr Respir Rev 2024:S1526-0542(24)00048-4. [PMID: 38937210 DOI: 10.1016/j.prrv.2024.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2024] [Accepted: 05/31/2024] [Indexed: 06/29/2024]
Abstract
High Flow Nasal Cannula therapy (HFNC) is a form of respiratory support for bronchiolitis. Recent evidence confirms HFNC reduces the risk of treatment escalation by nearly half (45%) compared to standard oxygen therapy (SOT), although most patients (75%) with mild-moderate respiratory distress manage well on SOT. The majority of children (60%) failing SOT respond well to HFNC making rescue use of HFNC a more cost-effective approach compared to its first-line use. HFNC is compared toCPAP in the setting of moderate to severe bronchiolitis. Patients on HFNC have a slightly elevated risk of treatment failure especially in severe bronchiolitis, but this does not translate to a significant difference in patient or healthcare centred outcomes. HFNC has improved tolerance, a lower complication rate and is more easily available in peripheral hospitals. It is therefore the preferred first line option followed by rescue CPAP. HFNC is clinically effective and safe to use in bronchiolitis of all severities.
Collapse
Affiliation(s)
- Emma C Alexander
- Paediatric Intensive Care Unit, St Mary's Hospital, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom.
| | - Toranj H Wadia
- Paediatric Intensive Care Unit, St Mary's Hospital, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom.
| | - Padmanabhan Ramnarayan
- Paediatric Intensive Care Unit, St Mary's Hospital, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Department of Surgery and Cancer, Imperial College London, London W2 1NY, United Kingdom.
| |
Collapse
|
2
|
D'Alessandro M, Fricano C, Abdulsatar F, Bechard N, Brar JS, Drouin O, Foulds JL, Giglia L, Gill PJ, Gupta R, Li P, McConnery J, Metcalf J, Sakran M, Seaton C, Sehgal A, Sirizzotti N, Mbuagbaw L, Wahi G. Understanding the use and outcomes of high-flow nasal cannula among infants admitted to Canadian hospitals with bronchiolitis (CanFLO): a protocol for a multicentre, retrospective cohort study. BMJ Open 2024; 14:e080197. [PMID: 38326253 PMCID: PMC10860006 DOI: 10.1136/bmjopen-2023-080197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Accepted: 01/24/2024] [Indexed: 02/09/2024] Open
Abstract
INTRODUCTION Bronchiolitis is the most common viral lower respiratory tract infection in children under 2 years of age. Respiratory support with high-flow nasal cannula (HFNC) is increasingly used in this patient population with limited understanding of the patients most likely to benefit and considerable practice variability of use. This study aims to understand the factors associated with failure of HFNC support among patients with bronchiolitis and to describe the current practice variations of HFNC use in patients with bronchiolitis in Canadian hospitals including fluid management and parameters to initiate, escalate and discontinue HFNC support. METHODS AND ANALYSIS This is a multicentre retrospective cohort study including hospitalised patients aged 0-24 months with bronchiolitis requiring support with HFNC between January 2017 and December 2021. Clinical data will be collected from patient medical records from Canadian hospitals (n=12), including academic and community centres. HFNC failure will be defined as the need for escalation to non-invasive or invasive mechanical ventilation. Factors associated with HFNC failure will be analysed using logistic regression. Descriptive statistics will be used to describe practice variations of HFNC utilisation and management. ETHICS AND DISSEMINATION Approval from the Research Ethics Boards (REBs) has been obtained for each participating study site prior to onset of data collection including Clinical Trials Ontario for all Ontario hospital sites and REBs from British Columbia Children's Hospital, Stollery Children's Hospital, Montreal Children's Hospital and CHU Sainte-Justine. Study results will be disseminated through presentation at national/international conferences and publication in high-impact, peer-reviewed journals.
Collapse
Affiliation(s)
| | - Chiara Fricano
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
| | - Farah Abdulsatar
- Department of Pediatrics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Nicole Bechard
- Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
| | - Jagraj Singh Brar
- Children's Hospital at London Health Sciences Centre, London, Ontario, Canada
| | - Olivier Drouin
- Pediatrics, University of Montreal, Montreal, Quebec, Canada
| | - Jessica L Foulds
- Department of Pediatrics, University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
| | - Lucia Giglia
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
- McMaster Children's Hospital, Hamilton, Ontario, Canada
| | - Peter J Gill
- Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Ronish Gupta
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
- McMaster Children's Hospital, Hamilton, Ontario, Canada
| | - Patricia Li
- Pediatrics, McGill University, Montreal, Quebec, Canada
| | | | | | - Mahmoud Sakran
- Department of Pediatrics, Queen's University, Kingston, Ontario, Canada
- Lakeridge Health Oshawa Hospital, Oshawa, Ontario, Canada
| | - Claire Seaton
- BC Children's Hospital, Vancouver, British Columbia, Canada
| | - Anupam Sehgal
- Department of Pediatrics, Queen's University, Kingston, Ontario, Canada
- Kingston Health Sciences Centre, Kingston, Ontario, Canada
| | | | - Lawrence Mbuagbaw
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
- Biostatistics Unit, Father Sean O'Sullivan Research Centre, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
| | - Gita Wahi
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
- McMaster Children's Hospital, Hamilton, Ontario, Canada
| |
Collapse
|
3
|
Ante‐Ardila N, Garnica CN, Umaña PM, Castañeda OLB, Cháves AJ, Naranjo MS, Piñeros JG, Bonilla C, Mejía LM, Mesa‐Rubio ML, Restrepo‐Gualteros S, Barrera P, Moreno‐Lopez S, Rueda‐Guevara P, Varela AR. Use of high‐flow cannula in pediatric patients with respiratory failure: A prospective cohort study in three high‐altitude hospitals. Health Sci Rep 2023; 6:e1182. [PMID: 37016619 PMCID: PMC10066842 DOI: 10.1002/hsr2.1182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 03/02/2023] [Accepted: 03/08/2023] [Indexed: 04/04/2023] Open
Abstract
Background and Aims Acute respiratory failure (ARF) is a common cause of morbimortality, and a frequent reason for admission to the pediatric intensive care unit (PICU). It requires a high‐flow oxygen device as treatment. Our aim is to determine the frequency and main indications for the use of high‐flow nasal cannula (HFNC), and the prevalence of HFNC failure and its main causes, in three hospitals Methods It is a multicenter prospective cohort study, developed in three hospitals in Bogota. Eligible patients were children older than 1 month and younger than 18 years who presented ARF and required management with an HFNC. The study was carried out between April 2020 and December 2021. The follow‐up was carried out at 1, 6, and 48 h after starting the management. Results Of 685 patients included in the study, 296 developed ARF. The prevalence of patients with ARF who required management with HFNC was 48%. The frequency of the pathologies that cause the ARF was: Bronchiolitis was the most frequent pathology (34.5%), followed by asthmatic crisis (15.5%) and pneumonia (12.7%). The average time of use of HFNC was 81.6 h. Regarding treatment failure with HFNC, 15 patients presented torpid evolution and required invasive mechanical ventilation, with a prevalence of therapeutic failure of the HFNC of 10.6%. Conclusion The use of HFNC is more frequent in patients with bronchiolitis, in children under 2 years of age and in males, which is in line with what has been reported in the literature. In addition, the failure rate of HFNC is low (10.6%), and it may be useful in other pathologies besides bronchiolitis, such as asthma, pneumonia, among others. It opens the possibility to continue evaluating the role of HFNC in pediatric pathology in new studies.
Collapse
Affiliation(s)
| | | | | | - Olga Lucía Baquero Castañeda
- Faculty of MedicineUniversidad de los AndesBogotaColombia
- Pediatrician Clínica Infantil ColsubsidioBogotáColombia
| | | | | | - Juan G. Piñeros
- Department of PediatricsUniversidad de los AndesBogotáColombia
- Faculty of MedicineUniversidad de los AndesBogotaColombia
- Fundación Santa Fe de BogotáBogotaColombia
| | - Carolina Bonilla
- Faculty of MedicineUniversidad de los AndesBogotaColombia
- Fundación Santa Fe de BogotáBogotaColombia
| | - Luz M. Mejía
- Faculty of MedicineUniversidad de los AndesBogotaColombia
- Instituto RooseveltBogotaColombia
| | - María L. Mesa‐Rubio
- Department of PediatricsUniversidad de los AndesBogotáColombia
- Faculty of MedicineUniversidad de los AndesBogotaColombia
| | - Sonia Restrepo‐Gualteros
- Faculty of MedicineUniversidad de los AndesBogotaColombia
- Fundación Santa Fe de BogotáBogotaColombia
| | - Pedro Barrera
- Faculty of MedicineUniversidad de los AndesBogotaColombia
| | | | | | | | | |
Collapse
|
4
|
Update on the Role of High-Flow Nasal Cannula in Infants with Bronchiolitis. CHILDREN-BASEL 2021; 8:children8020066. [PMID: 33498527 PMCID: PMC7909574 DOI: 10.3390/children8020066] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 01/13/2021] [Accepted: 01/15/2021] [Indexed: 11/17/2022]
Abstract
Bronchiolitis (BR), a lower respiratory tract infection mainly caused by respiratory syncytial virus (RSV), can be very severe. Presently, adequate nutritional support and oxygen therapy remain the only interventions recommended to treat patients with BR. For years, mild BR cases were treated with noninvasive standard oxygen therapy (SOT), i.e., with cold and poorly or totally non-humidified oxygen delivered by an ambient headbox or low-flow nasal cannula. Children with severe disease were intubated and treated with invasive mechanical ventilation (IMV). To improve SOT and overcome the disadvantages of IMV, new measures of noninvasive and more efficient oxygen administration have been studied. Bi-level positive air way pressure (BiPAP), continuous positive airway pressure (CPAP), and high-flow nasal cannula (HFNC) are among them. For its simplicity, good tolerability and safety, and the good results reported in clinical studies, HFNC has become increasingly popular and is now widely used. However, consistent guidelines for initiation and discontinuation of HFNC are lacking. In this narrative review, the role of HFNC to treat infants with BR is discussed. An analysis of the literature showed that, despite its widespread use, the role of HFNC in preventing respiratory failure in children with BR is not precisely defined. It is not established whether it can offer greater benefits compared to SOT and when and in which infants it can replace CPAP or BiPAP. The analysis of the results clearly indicates the need for multicenter studies and official guidelines. In the meantime, HFNC can be considered a safe and effective method to treat children with mild to moderate BR who do not respond to SOT.
Collapse
|